

# Jerome Doyen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9405739/publications.pdf>

Version: 2024-02-01

59  
papers

1,812  
citations

304743

22  
h-index

276875

41  
g-index

76  
all docs

76  
docs citations

76  
times ranked

3308  
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 inhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. <i>Clinical Lung Cancer</i> , 2022, 23, e252-e256.	2.6	10
2	Intensityâ€modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Costâ€effectiveness analysis. <i>Head and Neck</i> , 2022, 44, 431-442.	2.0	3
3	Propensity score analysis of radical proctectomy versus organ preservation using contact X-ray brachytherapy for rectal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 70-76.	1.7	2
4	Current practice in proton therapy delivery in adult cancer patients across Europe. <i>Radiotherapy and Oncology</i> , 2022, 167, 7-13.	0.6	23
5	Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma. <i>Cancers</i> , 2022, 14, 70.	3.7	7
6	Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse. <i>Clinical Oncology</i> , 2021, 33, e15-e21.	1.4	2
7	Contact X-ray brachytherapy for rectal cancer: Past, present, and future. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 795-800.	1.4	7
8	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
9	Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness. <i>BMC Cancer</i> , 2021, 21, 944.	2.6	3
10	Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors. <i>Radiotherapy and Oncology</i> , 2021, 161, 198-204.	0.6	2
11	Postsurgical geometrical variations of tumor bed and brainstem during photon and proton therapy for pediatric tumors of the posterior fossa: dosimetric impact and predictive factors. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1113-1123.	2.0	3
12	Present and Future Research on Anal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3895.	3.7	12
13	Role of proton therapy in reirradiation and in the treatment of sarcomas. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 550-553.	1.4	2
14	Fractionated Stereotactic Radiation Therapy for Pituitary Adenomas: An alternative escalating protocol of hypofractionated stereotactic radiotherapy delivering 35 Gy in 5 fractions. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, , .	1.4	2
15	RGD-functionalized magnetosomes are efficient tumor radioenhancers for X-rays and protons. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 23, 102084.	3.3	15
16	Radiotherapy for primary tumor in lung cancer with synchronous metastases: Overview from the past and proposal for the future. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 554-558.	1.4	1
17	VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. <i>Communications Biology</i> , 2020, 3, 579.	4.4	9
18	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 5198-5207.	7.0	66

#	ARTICLE	IF	CITATIONS
19	Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. <i>Bulletin Du Cancer</i> , 2020, 107, 946-958.	1.6	15
20	Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. <i>BMC Cancer</i> , 2020, 20, 599.	2.6	12
21	A brief history of contact X-ray brachytherapy 50 kVp. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 222-225.	1.4	10
22	Early Toxicities After High Dose Rate Proton Therapy in Cancer Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 613089.	2.8	4
23	Outcome and Patterns of Relapse in Childhood Parameningeal Rhabdomyosarcoma Treated With Proton Beam Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1043-1054.	0.8	21
24	In Reply to Gultekin and Yildiz. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1164-1165.	0.8	0
25	Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. <i>European Journal of Cancer</i> , 2019, 108, 1-16.	2.8	49
26	Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. <i>Radiotherapy and Oncology</i> , 2019, 132, 155-161.	0.6	42
27	Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. <i>Radiotherapy and Oncology</i> , 2018, 127, 239-245.	0.6	5
28	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 41-47.	4.4	32
29	Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial. <i>Brachytherapy</i> , 2018, 17, 407-414.	0.5	31
30	Changes in Ocular Subfoveal Choroidal Thickness After Carotid Endarterectomy Using Enhanced Depth Imaging Optical Coherence Tomography: A Pilot Study. <i>Angiology</i> , 2018, 69, 574-581.	1.8	17
31	Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2018, 70, 265-271.	7.7	43
32	Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. <i>European Journal of Cancer</i> , 2017, 72, 124-136.	2.8	36
33	Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. <i>Diseases of the Colon and Rectum</i> , 2017, 60, 785-791.	1.3	25
34	Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. <i>Annals of Oncology</i> , 2017, 28, 2436-2442.	1.2	72
35	Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy. <i>JAMA Dermatology</i> , 2017, 153, 1056.	4.1	13
36	Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma. <i>Oncogenesis</i> , 2017, 6, e354-e354.	4.9	49

#	ARTICLE	IF	CITATIONS
37	Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, e211-e220.	2.3	33
38	Immunotherapy for rectal carcinoma: Some stimulating data but still a long way to clinical evidence. <i>European Journal of Cancer</i> , 2016, 68, 70-72.	2.8	0
39	Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy. <i>Cancer Treatment Reviews</i> , 2016, 43, 104-112.	7.7	69
40	Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 369-374.	2.8	13
41	New Neoadjuvant Treatment Strategies for Non-Metastatic Rectal Cancer (M0). <i>Current Colorectal Cancer Reports</i> , 2015, 11, 289-297.	0.5	0
42	Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud "Acta Oncologica" experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients. <i>Acta Oncologica</i> , 2015, 54, 550-556.	1.8	30
43	Results of age-dependent anal canal cancer treatment: A single centre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 460-464.	0.9	14
44	Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. <i>Biochemical and Biophysical Research Communications</i> , 2014, 451, 54-61.	2.1	95
45	Magnetic resonance guided focalised ultrasound thermo-ablation: A promising oncologic local therapy. <i>Diagnostic and Interventional Imaging</i> , 2014, 95, 339-343.	3.2	4
46	Aims of Combined Modality Therapy in Rectal Cancer (M0). <i>Recent Results in Cancer Research</i> , 2014, 203, 153-169.	1.8	14
47	Identification of a DNA methylation signature to predict disease-free survival in locally advanced rectal cancer. <i>Oncotarget</i> , 2014, 5, 8123-8135.	1.8	20
48	Predictive Factors for Early and Late Local Toxicities in Anal Cancer Treated by Radiotherapy in Combination With or Without Chemotherapy. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 1125-1133.	1.3	18
49	Conjunctival melanomas and proton beam therapy. <i>Acta Ophthalmologica</i> , 2013, 91, e647-e647.	1.1	10
50	Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. <i>Frontiers in Oncology</i> , 2013, 2, 199.	2.8	61
51	<i>EGFR</i> , <i>KRAS</i> , <i>BRAF</i> , and <i>HER2</i> molecular status in brain metastases from 77 <i>NSCLC</i> patients. <i>Cancer Medicine</i> , 2013, 2, 296-304.	2.8	32
52	MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. <i>Cell Death and Disease</i> , 2013, 4, e544-e544.	6.3	192
53	Renal cell carcinoma and a constitutional t(11;22)(q23;q11.2): case report and review of the potential link between the constitutional t(11;22) and cancer. <i>Cancer Genetics</i> , 2012, 205, 603-607.	0.4	4
54	Towards a "Lyon molecular signature" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx M0 to be the basis of a molecular signature. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2012, 16, 688-696.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Circulating tumor cells in prostate cancer: A potential surrogate marker of survival. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 241-256.	4.4	68
56	CÂ“ur et radiations ionisantesÂ: les complications aiguÃ«s et tardives Ã ne pas mÃ©connaÃ®tre. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2011, 2011, 7-11.	0.0	1
57	Aromatase inhibition in male breast cancer patients: biological and clinical implications. <i>Annals of Oncology</i> , 2010, 21, 1243-1245.	1.2	76
58	Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2008, 141, 744-745.	2.5	5
59	Prognostic factors in 1038 women with metastatic breast cancer. <i>Annals of Oncology</i> , 2008, 19, 2012-2019.	1.2	301